^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Pancreatic Adenocarcinoma
    Drug:Rubraca (rucaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/24/2022
    Excerpt:
    Pancreatic Adenocarcinoma...Useful in certain circumstances...Rucaparib (for germline or somatic BRCA1/2 or PALB2 mutations)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Peritoneal Cancer)
    New
    Excerpt:
    RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.